| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
107,824 |
105,948 |
$10.15M |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
174,158 |
171,236 |
$7.20M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
45,509 |
44,701 |
$6.01M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
26,899 |
26,250 |
$950K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,670 |
11,474 |
$913K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
5,059 |
4,992 |
$818K |
| Q3014 |
Telehealth originating site facility fee |
31,279 |
30,801 |
$797K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
30,976 |
30,583 |
$623K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,500 |
4,426 |
$446K |
| 99215 |
Prolong outpt/office vis |
2,791 |
2,760 |
$337K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
16,624 |
16,415 |
$241K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,226 |
5,176 |
$232K |
| 99205 |
Prolong outpt/office vis |
1,241 |
1,236 |
$207K |
| 99051 |
|
19,619 |
19,133 |
$98K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,683 |
3,315 |
$91K |
| 81025 |
|
9,481 |
9,329 |
$68K |
| 81003 |
|
23,535 |
23,094 |
$41K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,146 |
2,072 |
$33K |
| 99000 |
|
7,739 |
7,603 |
$30K |
| S9083 |
Global fee urgent care centers |
210 |
205 |
$29K |
| 20552 |
|
339 |
330 |
$13K |
| 36415 |
Collection of venous blood by venipuncture |
3,324 |
3,273 |
$8K |
| 71046 |
Radiologic examination, chest; 2 views |
288 |
283 |
$6K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
1,545 |
1,486 |
$3K |
| 87301 |
|
261 |
255 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
152 |
146 |
$1K |
| 93000 |
|
110 |
108 |
$1K |
| 80047 |
|
25 |
25 |
$265.65 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
314 |
309 |
$158.13 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
222 |
218 |
$127.09 |
| 86580 |
|
21 |
21 |
$113.54 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
83 |
80 |
$105.81 |
| 85014 |
|
25 |
25 |
$50.86 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
48 |
48 |
$38.66 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
58 |
57 |
$36.11 |
| 82962 |
|
13 |
12 |
$33.52 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
12 |
12 |
$26.35 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
40 |
39 |
$5.09 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
28 |
28 |
$2.54 |
| A9150 |
Non-prescription drugs |
206 |
199 |
$1.38 |
| 3008F |
|
17,289 |
16,933 |
$0.00 |
| 3075F |
|
1,402 |
1,381 |
$0.00 |
| 3079F |
|
2,870 |
2,814 |
$0.00 |
| 3080F |
|
1,852 |
1,817 |
$0.00 |
| 3074F |
|
7,563 |
7,429 |
$0.00 |
| 1125F |
|
12 |
12 |
$0.00 |
| 3077F |
|
2,092 |
2,043 |
$0.00 |
| 3078F |
|
6,552 |
6,442 |
$0.00 |
| 1160F |
|
1,423 |
1,392 |
$0.00 |
| 1159F |
|
3,043 |
2,974 |
$0.00 |